Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
7 studies found for:    gdc-0973 | Open Studies | Exclude Unknown
Show Display Options
Rank Status Study
1 Recruiting Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Conditions: Melanoma;   Metastatic Melanoma
Interventions: Drug: Vemurafenib;   Drug: Bevacizumab;   Drug: Cobimetinib
2 Not yet recruiting Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases
Condition: Melanoma
Interventions: Drug: Vemurafenib;   Drug: Cobimetinib
3 Recruiting A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors
Condition: Neoplasms
Interventions: Drug: Cobimetinib;   Drug: MPDL3280A
4 Recruiting A Study of MEHD7945A and Cobimetinib (GDC-0973) in Patients With Locally Advanced or Metastatic Cancers With Mutant KRAS
Condition: Neoplasms
Interventions: Drug: MEHD7945A;   Drug: cobimetinib
5 Recruiting A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Vemurafenib (Zelboraf®) or Vemurafenib Plus Cobimetinib in Patients With Previously Untreated BRAFV600-Mutation Positive Metastatic Melanoma
Condition: Malignant Melanoma
Interventions: Drug: MPDL3280A;   Drug: Vemurafenib (Zelboraf®);   Drug: cobimetinib
6 Not yet recruiting Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases
Condition: Active Melanoma Brain Metastases
Interventions: Drug: Cobimetinib;   Drug: Vemurafenib
7 Recruiting A Phase I/II/Pharmacodynamic Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane to Inhibit Autophagy in Pancreatic Cancer
Conditions: Advanced Adenocarcinoma;   Metastatic Adenocarcinoma
Interventions: Drug: Hydroxychloroquine (HCQ);   Drug: Gemcitabine

Indicates status has not been verified in more than two years